Cell therapy for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental cell therapy called CCTx-001 for people with acute myeloid leukemia that has not responded to standard treatments or has come back. The treatment involves collecting your own immune cells, engineering them, and giving them back to attack the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia that has returned or not responded to at least two prior treatments.
- You must be able to have a procedure called leukapheresis, which collects your white blood cells for the treatment.
- Your overall health should be good, able to manage daily activities (ECOG score 1 or less).
- You must not have had a stem cell transplant within the last 3 months, and any transplant-related immune issues should be resolved.
- Your organs (kidneys, liver, heart, lungs) must be functioning well enough to participate.
- You must be 18 years or older and willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new type of cell therapy that uses your own immune cells (T cells) that have been changed in the lab to find and attack leukemia cells that have a marker called CD84. It is for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments.
This trial tests an experimental cell therapy (called Hema-NeoTIL01) for people with acute leukemia that has come back or not responded to standard treatments. The therapy uses your own immune cells to try to attack and destroy the leukemia cells.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.